Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 11 February 2026

Sec. Breast Cancer

Volume 16 - 2026 | https://doi.org/10.3389/fonc.2026.1796339

Correction: Beyond surface dose: subcutaneous dose escalation underlies TomoTherapy’s skin toxicity in breast radiotherapy

This article is a correction to:

  1. Beyond surface dose: subcutaneous dose escalation underlies TomoTherapy’s skin toxicity in breast radiotherapy

    1. Read original article
Jiao XueJiao Xue1Wenjun ZhaoWenjun Zhao2Chenchen Wu*Chenchen Wu1*
  • 1Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 2State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China

A Correction on
Beyond surface dose: subcutaneous dose escalation underlies TomoTherapy’s skin toxicity in breast radiotherapy

By Xue J, Zhao W and Wu C (2026) Front. Oncol. 16:1760716. doi: 10.3389/fonc.2026.1760716

There was a mistake in the captions of Figures 1 and 3 as published. The captions for Figures 1 and 3 were erroneously swapped. The corrected captions of Figures 1 and 3 appear below.

Figures 1

“Comparison of dosimetric parameters between Synergy and TOMO groups.”

Figures 3

“Comparison of dosimetric parameters within the PTV-projected adjacent superficial tissue (P-PAST) between Synergy and TOMO groups.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: acute skin toxicity, breast cancer radiotherapy setup, helical tomotherapy (TOMO), P-PAST, volumetric modulated arc therapy (VMAT)

Citation: Xue J, Zhao W and Wu C (2026) Correction: Beyond surface dose: subcutaneous dose escalation underlies TomoTherapy’s skin toxicity in breast radiotherapy. Front. Oncol. 16:1796339. doi: 10.3389/fonc.2026.1796339

Received: 26 January 2026; Accepted: 28 January 2026;
Published: 11 February 2026.

Edited and reviewed by:

Atsuto Katano, The University of Tokyo Hospital, Japan

Copyright © 2026 Xue, Zhao and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chenchen Wu, d2NjMjExOUBzdWRhLmVkdS5jbg==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.